Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2019-03-08 M&A Activity
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
425 Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a merger agreement amendment, a settlement agreement, and proxy solicitation information related to a merger transaction. It references a Definitive Proxy Statement and other filings but does not itself contain full financial statements or detailed financial performance data. The document is primarily an announcement of material definitive agreements and updates related to a merger transaction. Therefore, it fits best into the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2019-03-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing with the SEC, specifically a Definitive Additional Materials filing supplementing a Definitive Proxy Statement related to a special meeting of stockholders. It discusses details about a merger agreement, settlement negotiations, and amendments to the merger terms. The document is clearly a proxy solicitation material, providing additional disclosures to shareholders to inform their voting decisions regarding the merger. It is not an annual report, earnings release, or other financial report. The presence of terms like 'Definitive Proxy Statement', 'special meeting of stockholders', and 'solicitation of proxies' confirms this is proxy solicitation information. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length and content support a high confidence score.
2019-03-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes termination of a material definitive agreement, sublease agreements, a proposed settlement related to grants and loans, and details about a merger proxy statement and amendments. It also references a Definitive Proxy Statement and solicitation of proxies for a merger. The document is not a full annual or quarterly report, nor is it a transcript or earnings release. It is a regulatory announcement of material events and updates related to corporate actions and legal settlements. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-03-01 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The content includes details about a lease termination, a sublease agreement, a proposed settlement related to grants and loans, and information about a planned merger. It also references a Definitive Proxy Statement filed earlier and discusses amendments to the merger agreement. The document is not a full financial report but rather an announcement of material events and updates related to corporate transactions and agreements. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2019-03-01 English
Regulatory Filings 2019
Regulatory Filings
2019-02-20 English
Regulatory Filings 2019
Regulatory Filings
2019-02-15 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.